Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL8727242 | 0.85 | NOS2 (0.39) | — | |
| SCHEMBL7702747 | 0.82 | DGAT1 (0.39) | CA2DGAT1ALDH1A1 | |
| SCHEMBL8723763 | 0.78 | PRSS1 (0.42) | CA2DGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL6484945 | 0.78 | F2 (0.49) | ALDH1A1 | |
| SCHEMBL6371844 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 | |
| SCHEMBL30924754 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 | |
| SCHEMBL825679 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 | |
| SCHEMBL29565533 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 | |
| SCHEMBL29356868 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 | |
| SCHEMBL27902671 | 0.77 | DPP4 (0.60) | DPP4DPP8ANPEPFAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | DPP4 551/4885DPP8 346/4885ANPEP 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.